Livzon Pharmaceutical Group Inc
SZSE:000513
Livzon Pharmaceutical Group Inc
Interest Income Expense
Livzon Pharmaceutical Group Inc
Interest Income Expense Peer Comparison
Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors
Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Livzon Pharmaceutical Group Inc
SZSE:000513
|
Interest Income Expense
¥358.8m
|
CAGR 3-Years
12%
|
CAGR 5-Years
14%
|
CAGR 10-Years
66%
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Interest Income Expense
¥1.1B
|
CAGR 3-Years
52%
|
CAGR 5-Years
82%
|
CAGR 10-Years
N/A
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Interest Income Expense
¥134.5m
|
CAGR 3-Years
7%
|
CAGR 5-Years
4%
|
CAGR 10-Years
23%
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Interest Income Expense
¥429.9m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
4%
|
CAGR 10-Years
30%
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Interest Income Expense
¥1.1B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
37%
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Interest Income Expense
-¥20.1m
|
CAGR 3-Years
-107%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Livzon Pharmaceutical Group Inc's Interest Income Expense?
Interest Income Expense
358.8m
CNY
Based on the financial report for Mar 31, 2024, Livzon Pharmaceutical Group Inc's Interest Income Expense amounts to 358.8m CNY.
What is Livzon Pharmaceutical Group Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 10Y
66%
Over the last year, the Interest Income Expense growth was 42%. The average annual Interest Income Expense growth rates for Livzon Pharmaceutical Group Inc have been 12% over the past three years , 14% over the past five years , and 66% over the past ten years .